TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：2

作者：

Bloom, Stuart ^{[1
]}

Lichtenstein, Gary R. ^{[2
]}

Loftus, Edward V. ^{[3
]}

Lawendy, Nervin ^{[4
]}

Friedman, Gary S. ^{[4
]}

Zhang, Haiying ^{[4
]}

Wang, Wenjin ^{[4
]}

Thorpe, Andrew J. ^{[4
]}

Nduaka, Chudy I. ^{[4
]}

Su, Chinyu ^{[4
]}

机构：

[1] Ucl Hosp Bhs Fdn Trust, London, England

[2] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[3] Mayo Clin, Rochester, MN USA

[4] Pfizer Inc, Collegeville, PA USA

来源：

GUT | 2018年 / 67卷

关键词：

D O I：

10.1136/gutjnl-2018-BSGAbstracts.123

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PTU-001

引用

页码：A62 / A63

页数：2

共 50 条

[41] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
Wroe, S.
Duncan, R.
[J]. EPILEPSIA, 2006, 47 : 138 - 138
[42] SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
Panaccione, Remo
Lichtenstein, Gary R.
Nakase, Hiroshi
Armuzzi, Alessandro
Kucharzik, Torsten
Levy, Gweneth
Palac, Hannah
Kujawski, Michelle
Klaff, Justin
Cheon, Jae Hee
[J]. GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1100
[43] Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
Panaccione, R.
Lichtenstein, G.
Nakase, H.
Armuzzi, A.
Kucharzik, T.
Levy, G.
Palac, H.
Kujawski, M.
Klaff, J.
Cheon, J. H.
[J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 644 - 646
[44] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN-LABEL EXTENSION STUDY
Genovese, Mark C.
Kremer, Joel
Zhong, Sheng
Friedman, Alan
[J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S85 - S85
[45] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
Baker, Milton
Chalabi, Youb
Genovese, Mark
Taylor, Peter
Schlichting, Douglas
Beattie, Scott
Macias, William
Keystone, Edward
[J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
[46] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Papp, Kim A.
Krueger, James G.
Feldman, Steven R.
Langley, Richard G.
Thaci, Diamant
Torii, Hideshi
Tyring, Stephen
Wolk, Robert
Gardner, Annie
Mebus, Charles
Tan, Huaming
Luo, Yingchun
Gupta, Pankaj
Mallbris, Lotus
Tatulych, Svitlana
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
[47] Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Paik, Julie
Albayda, Jemima
Tiniakou, Eleni
Purwin, Grazyna
Koenig, Andrew
Christopher-Stine, Lisa
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[48] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Studies up to 36 Months.
Wollenhaupt, J.
Silverfield, J. C.
Lee, E. B.
Wood, S.
Soma, K.
Wang, L.
Nakamura, H.
Komuro, Y.
Nduaka, C. I.
Gruben, D.
Zwillich, S. H.
Bradley, J. D.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S152 - S153
[49] CLINICAL OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB MONOTHERAPY IN THE OPEN-LABEL LONG-TERM EXTENSION
Fleischmann, R.
Wollenhaupt, J.
Wang, L.
Maniccia, A.
Kwok, K.
Takiya, L.
van Vollenhoven, R.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 259 - 260
[50] LONG-TERM SPARSENTAN TREATMENT IN FSGS IN THE DUET OPEN-LABEL EXTENSION (OLE)
Trachtman, Howard
Srivastava, Tarak
Tesar, Vladimir
Campbell, Kirk N.
Rheault, Michelle N.
Komers, Radko
Murphy, Edward
Prasad, Andy
Gesualdo, Loreto
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S99 - S99

← 1 2 3 4 5 →